Skip to main content

7 Result(s)

within S. Eckhardt Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

    The purpose of this phase I study was to evaluate the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), the recommended dose for phase II study, pharmacokinetics, and antitumor activity of TZT-1027 (...

    J. Horti, E. Juhasz, Z. Monostori, K. Maeda… in Cancer Chemotherapy and Pharmacology (2008)

  2. No Access

    Article

    Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study

    Between April 1986 and May 1989 a multicéntre study was conducted to evaluate the efficacy of a 4-h intravenous infusion of 1000 mg/m2 5-fluorouracil (5-FU) followed by a 1-h infusion of 25 mg/m2 cisplatin (CDDP)...

    J. Jassem, F. Gyergvay, S. Kerpel-Fronius… in Cancer Chemotherapy and Pharmacology (1993)

  3. No Access

    Article

    Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG)

    Diacetyldianhydrogalactitol (DADAG), a new alkylating sugar alcohol derivative, was administered as single, 30-min infusions in doses ranging from 390 to 1200 mg/m2. The dose-limiting toxicity was myelosuppressio...

    S. Kerpel-Fronius, V. Erdélyi-Tóth, F. Gyergyay… in Cancer Chemotherapy and Pharmacology (1986)

  4. No Access

    Article

    Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG)

    Diacetyldianhydrogalactitol (DADAG), a new alkylating hexitol derivative, was given in 30-min infusions for 5 consecutive days or as a single high-dose administration. The parent drug was eliminated in a bipha...

    V. Erdélyi-Tóth, S. Kerpel-Fronius, B. Kanyár… in Cancer Chemotherapy and Pharmacology (1986)

  5. No Access

    Article

    The fate of Drotaverine-Acephyllinate in rat and man II. Human pharmacokinetics of Drotaverine-14C-Acephyllinate

    Pharmacokinetics of Drotaverine-Acephyllinate, Chinoin was investigated in seven male volunteers using14C labelled drug. Drotaverine-Acephyllinate was administered at a 100 mg single oral dose. Measurements of to...

    Z. Vargay, T. Deutsch, I. Szatmári, T. SzÜts… in European Journal of Drug Metabolism and Ph… (1984)

  6. No Access

    Article

    Dibromodulcitol plus bleomycin compared with bleomycin alone in head and neck cancer

    Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemot...

    B. F. Issell, G. Borsos, J. C. D'Aoust, F. Banhidy… in Cancer Chemotherapy and Pharmacology (1982)

  7. No Access

    Chapter

    Clinical Pharmacological Studies with Formyl-Leurosin in Malignant Diseases

    New cytostatic agents may be new molecules or analogues of existing antitumour drugs. In a recent survey the ratio between these two types of compounds was estimated 1 : 8, which means that far more analogues ...

    S. Eckhardt, I. Hindy, E. Farkas in Chemotherapy (1976)